Furthermore, we demonstrate that ERRα is indispensable for estrogen/ERα signaling for efficient VLDL-TG secretion and prevent NAFLD/NASH development under pharmacological manipulations and genetic modifications. The gene discussed is ESRRA; the disease is metabolic dysfunction-associated steatotic liver disease.